BioSpace News Archive

Hillstream BioPharma, Inc. announced that an abstract highlighting the progress of the Quatramer-based Ferroptosis Inducer, HSB-1216, are available as a poster at the 34th EORTC- NCI - AACR Symposium in Barcelona taking place from October 26 -28, 2022.

Patients Choice Laboratories, a leading provider of comprehensive laboratory testing throughout the U.S., announced that it has acquired Infinity Laboratories, LLC located in Bridgeport, TX.

BioSkryb Genomics, a pioneer in developing scientifically advanced single-cell analysis molecular tools, announced a multi-year agreement with Cooper Genomics, a leader in the reproductive health market, to license BioSkryb’s proprietary genomic amplification technology.

Revamp Medical, a pioneering developer of a percutaneous device for the treatment of acute heart failure (AHF), today announced the enrollment of the first patient in a multi-site Early Feasibility Study (EFS), the DORAYA-HF.

ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the further expansion of their leadership team and clinical development capabilities through the appointment of Feriandas Greblikas, M.D. as Vice President of Clinical Development.

Australian industrial biotechnology leader MicroBioGen (“the Company”) officially opened its state-of-the-art laboratories in Macquarie Park in Northern Sydney this weekend. The labs will produce world-leading micro-organisms that are essential to industries worth over US$2 trillion per year, including biofuels, alternative proteins, space exploration, sustainable human foods and animal feed.

People with spinal muscular atrophy are relying on recently approved condition-specific treatments and are hopeful the treatment pipeline can continue to have a positive impact, according to a recent survey conducted by Health Union, the leader in social health.

Treventis Corporation, a privately held biotechnology company, announced that their proposal to preclinically develop a small molecule anti-tau misfolding drug has been awarded funding totaling $2,977,166 by the Congressionally Directed Medical Research Programs, part of the DOD.

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient has been dosed in the Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic (PK/PD) Study in Cancer Patients (RETRO).

The global clinical workflow solutions market size accounted for USD 9.27 billion in 2022 and is expected to surpass around USD 23.99 billion by 2030, growing at a CAGR of 12.6% from 2022 to 2030.